UroGen Pharma's top three insider shareholders as of April 17, 2026 are Ran Nussbaum (Director, 1.48Mn shares), Arie Belldegrun (Director, 408.69K shares), Elizabeth A. Barrett (Chief Executive Officer, 326.69K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Ran Nussbaum | - | 0 | 1,481,927 | 25 Oct, 2022 |
| Arie Belldegrun | - | 408,693 | 0 | 16 Sep, 2022 |
| Elizabeth A. Barrett | Chief Executive Officer | 326,691 | 0 | 02 Feb, 2023 |
| Mark Schoenberg | Chief Medical Officer | 144,985 | 0 | 04 Feb, 2026 |
| Fred E Cohen | - | 0 | 69,339 | 28 Jul, 2023 |
| Jason Drew Smith | General Counsel | 55,588 | 0 | 11 Feb, 2026 |
| Dong Kim | Chief Financial Officer | 37,753 | 0 | 12 Sep, 2024 |
| Molly Henderson | Chief Financial Officer | 5,248 | 0 | 01 Feb, 2022 |
| James A. Jr. Robinson | - | 4,000 | 0 | 27 Feb, 2026 |
| Chris Degnan | Chief Financial Officer | 2,280 | 0 | 09 Oct, 2025 |
| Stuart Holden | - | 2,000 | 0 | 01 Dec, 2025 |
| Daniel George Wildman | - | 2,000 | 0 | 01 Dec, 2025 |
| Cynthia M Butitta | - | 2,000 | 0 | 01 Dec, 2025 |
| Leana Wen | - | 2,000 | 0 | 01 Dec, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Feb, 2025 | James A. Jr. Robinson | ordinary shares | A | 2,000 | - | 4,000 | D | M |
| 26 Feb, 2025 | James A. Jr. Robinson | Restricted Stock Unit | D | 2,000 | $0.00 | 4,000 | D | M |
| 31 Jan, 2026 | Elizabeth A. Barrett | Restricted Stock Units | A | 153,195 | $0.00 | 153,195 | D | A |
| 31 Jan, 2026 | Jason Drew Smith | Ordinary Shares | A | 5,500 | - | 55,472 | D | M |
| 03 Feb, 2026 | Jason Drew Smith | Ordinary Shares | D | 2,654 | $19.69 | 52,934 | D | S |
| 31 Jan, 2026 | Jason Drew Smith | Ordinary Shares | A | 3,333 | - | 58,805 | D | M |
| 03 Feb, 2026 | Jason Drew Smith | Ordinary Shares | D | 1,608 | $19.69 | 51,326 | D | S |
| 31 Jan, 2026 | Jason Drew Smith | Ordinary Shares | A | 6,667 | - | 49,972 | D | M |
| 03 Feb, 2026 | Jason Drew Smith | Ordinary Shares | D | 3,217 | $19.69 | 55,588 | D | S |
| 31 Jan, 2026 | Jason Drew Smith | Restricted Stock Units | D | 5,500 | $0.00 | 5,500 | D | M |
| 31 Jan, 2026 | Jason Drew Smith | Restricted Stock Units | D | 3,333 | $0.00 | 6,667 | D | M |
| 31 Jan, 2026 | Jason Drew Smith | Restricted Stock Units | D | 6,667 | $0.00 | 0 | D | M |
| 31 Jan, 2026 | Jason Drew Smith | Restricted Stock Units | A | 32,609 | $0.00 | 32,609 | D | A |
| 03 Feb, 2026 | Mark Schoenberg | Ordinary Shares | D | 1,844 | $19.69 | 150,514 | D | S |
| 03 Feb, 2026 | Mark Schoenberg | Ordinary Shares | D | 1,843 | $19.69 | 148,671 | D | S |
| 03 Feb, 2026 | Mark Schoenberg | Ordinary Shares | D | 3,686 | $19.69 | 144,985 | D | S |
| 31 Jan, 2026 | Mark Schoenberg | Ordinary Shares | A | 3,333 | - | 145,692 | D | M |
| 31 Jan, 2026 | Chris Degnan | Restricted Stock Units | A | 32,609 | $0.00 | 32,609 | D | A |
| 31 Jan, 2026 | Mark Schoenberg | Ordinary Shares | A | 6,666 | - | 152,358 | D | M |
| 31 Jan, 2026 | Mark Schoenberg | Ordinary Shares | A | 3,334 | - | 142,359 | D | M |